HRV Pharma Invests Rs 150 Crore to Expand Peptide and Oncology API Manufacturing
HRV Pharma announced a Rs 150 crore investment to expand its capabilities in synthetic peptides and high-potency oncology active pharmaceutical ingredients (APIs). The company plans to invest Rs 40-50 crore in a dedicated cGMP peptide manufacturing facility through a partnership with Arene Lifesciences, and approximately Rs 100 crore in a manufacturing facility for oncology APIs. HRV Pharma aims to maintain its asset-light model while securing capacity and control over intellectual property and commercialization rights in these specialized pharmaceutical segments.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (74/100). Lens Score 38/100.
Outlets measured: news18, mint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (74–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
mint broke this story on 7 Sept, 11:53 am. Other outlets followed.
- 1